Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and ther
Author: ["J.I. Mayordomo","T. Zorina","W.J. Storkus","L. Zitvogel","C. Celluzzi","L.D. Falo","C.J. Melief","S.T. Ildstad","W. Martin Kast","A.B. Deleo","M.T. Lotze"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Dendritic cells, the most potent ‘professional’ antigen-presenting cells, hold promise for improving the immunotherapy of cancer. In three different well-characterized tumour models, naive mice injected with bone marrow-derived dendritic cells prepulsed with tumour-associated peptides previously characterized as being recognized by class I major histocompatibility complex-restricted cytotoxic T lymphocytes, developed a specific T-lymphocyte response and were protected against a subsequent lethal tumour challenge. Moreover, in the C3 sarcoma and the 3LL lung carcinoma murine models, treatment of animals bearing established macroscopic tumours (up to 1 cm2 in size) with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases. These results support the clinical use of tumour peptide-pulsed dendritic cells as components in developing effective cancer vaccines and therapies.
Cite this article
Mayordomo, J., Zorina, T., Storkus, W. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1, 1297–1302 (1995). https://doi.org/10.1038/nm1295-1297
